Vir Biotechnology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.6B | $1.1B |
| Operating income | -$479.3M | -$587.2M | -$684.3M | $833.1M | $420.8M |
| Cost of revenue | $26,000 | $845,000 | $2.8M | $146.3M | $65.9M |
| Cash from operations | -$391.8M | -$446.4M | -$778.8M | $1.7B | -$47.6M |
| Capital expenditure | $4.8M | $7.3M | $21.6M | $68.0M | $21.8M |
| Free cash flow | -$396.6M | -$453.7M | -$800.4M | $1.6B | -$69.4M |
| Impairments | $0 | $0 | $7.7M | $0 | $0 |
| Total assets | $1.0B | $1.4B | $1.9B | $2.8B | $2.0B |
| Total liabilities | $237.5M | $248.4M | $328.8M | $724.1M | $522.4M |
Shares outstanding 168.7M · Free float 89.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.